ArticleACS biomaterials science & engineering2017
Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles.
Article in ACS biomaterials science & engineering, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Peptide Antigen Modifications Influence the On-Target and Off-Target Antibody Response for an Influenza Subunit Vaccine.Vaccines · 2025Article
- Application of Nanomedicine in Tumor Targeting Inflammatory Pathway.Current medicinal chemistry · 2025Review
- M2e-Derived Peptidyl and Peptide Amphiphile Micelles as Novel Influenza Vaccines.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis.Bioactive materials · 2023Article
- CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.Molecules (Basel, Switzerland) · 2022Article
- Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Peptide-based supramolecular vaccine systems.Acta biomaterialia · 2021Review
- miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype.Biomaterials · 2021Article
- Micellar Drug Delivery Systems Based on Natural Biopolymers.Polymers · 2021Review
- CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles.Bioengineering & translational medicine · 2020Article
- Collagenase-Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis.Advanced therapeutics · 2020Article
- Peptide-based targeting of immunosuppressive cells in cancer.Bioactive materials · 2020Review
- Hydroxyapatite-binding micelles for the detection of vascular calcification in atherosclerosis.Journal of materials chemistry. B · 2019Article
- Mechanosensing and Mechanoregulation of Endothelial Cell Functions.Comprehensive Physiology · 2019Review
- Shape Effects of Peptide Amphiphile Micelles for Targeting Monocytes.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Monocyte chemoattractant protein-1 (MCP-1) stimulates the migration of monocytes to inflammatory sites, leading to the progression of many diseases. Recently, we described a monocyte-targeting peptide amphiphile micelle (MCP-1 PAM) incorporated with the chemokine receptor CCR2 binding motif of MCP-1, which has a high affinity for monocytes in atherosclerotic plaques. We further report here the biomimetic components of MCP-1 PAMs and the influence of the nanoparticle upon binding to monocytes. We report that MCP-1 PAMs have enhanced secondary structure compared to the MCP-1 peptide. As a result, MCP-1 PAMs displayed improved binding and chemoattractant properties to monocytes, which upregulated the inflammatory signaling pathways responsible for monocyte migration. Interestingly, when MCP-1 PAMs were incubated in the presence of prostate cancer cells in vitro, the particle displayed anticancer efficacy by reducing CCR2 expression. Given that monocytes play an important role in tumor cell migration and invasion, our results demonstrate that PAMs can improve the native biofunctional properties of the peptide and may be used as an effective inhibitor to prevent chemokine-receptor interactions that promote disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.